This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

8 Stocks Rising on Monster Volume

Stocks in this article: ACHNVVUSPMFGFSLRWWWWCBRLROVI

Achillion Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Achillion Pharmaceuticals (ACHN) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. The stock is trading up 23.4% at $10.80 in recent trading.

Today's Volume: 5 million

Average Volume: 1.4 million

Volume % Change: 401%

>>5 Biotech Stocks for 2012

Shares of ACHN are soaring today after Gilead Sciences (GILD) reported disappointing trial results for its experimental hepatitis C drug. Shares of ACHN, along with Vertex Pharmaceutical (VRTX) and Idenix Pharmaceutical (IDIX), are ripping higher because they are rival hepatitis C drug developers to Gilead.

From a technical perspective, ACHN is gapping up huge today on monster volume back above its 50-day moving average of $9.34.

Traders should now watch for a sustained high-volume move and close near its daily high of $11.14 to signal that ACHN wants to trend much higher. At last check, the stock is trading at $10.80 and volume is well above its average of 1.4 million shares. If we get that strong close today, then traders should continue to look for long biased trades that take this stock back towards its next major overhead resistance levels at $12.46 to $12.95 in the near future.

2 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs